Population based study on the progress in survival of primarily metastatic lung cancer patients in Germany.
Cancer registry
Germany
Lung cancer
Survival
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 Jul 2024
11 Jul 2024
Historique:
received:
24
03
2024
accepted:
01
07
2024
medline:
12
7
2024
pubmed:
12
7
2024
entrez:
11
7
2024
Statut:
epublish
Résumé
Lung cancer is known for its high mortality; many patients already present with metastases at the time of diagnosis. The aim of this study is to assess the impact of new treatment strategies on the survival of primarily metastatic lung cancer patients and to analyze the differences in outcomes between non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) patients. Population-based data, provided by the Robert-Koch Institute in Germany, was used and patients diagnosed between 2007 and 2018 were included in the study. We differentiated between NSCLC and SCLC patients and analyzed the survival over time for both sexes separately, using the Kaplan-Meier method. To evaluate survival advantages, we calculated multivariable hazard ratios. In total, 127,723 patients were considered for the study. We observed a moderate increase in survival over time. All patients showed an increased survival rate when undergoing chemotherapy. Minimal to no increase in survival was shown in NSCLC patients when receiving radiotherapy, whereas SCLC patients' survival time did benefit from it. NSCLC patients receiving immunotherapy showed an increase in survival as well. It can be concluded that advancements in radiotherapy, the application of chemotherapy, and the introduction of immunotherapies lead to an increased survival time of both NSCLC and SCLC primarily metastatic lung cancer patients.
Identifiants
pubmed: 38992115
doi: 10.1038/s41598-024-66307-3
pii: 10.1038/s41598-024-66307-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
16005Informations de copyright
© 2024. The Author(s).
Références
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249. https://doi.org/10.3322/caac.21660 (2021).
doi: 10.3322/caac.21660
pubmed: 33538338
Robert Koch-Institut (publ.) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (publ). Krebs in Deutschland für 2017/2018. https://doi.org/10.25646/8353 (2021).
Groome, P. A. et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J. Thorac. Oncol. 2(8), 694–705. https://doi.org/10.1097/JTO.0b013e31812d05d5 (2007).
doi: 10.1097/JTO.0b013e31812d05d5
pubmed: 17762335
Woodard, G. A., Jones, K. D. & Jablons, D. M. Lung Cancer staging and prognosis. Cancer Treatm. Res. 170, 47–75. https://doi.org/10.1007/978-3-319-40389-2_3 (2016).
doi: 10.1007/978-3-319-40389-2_3
Catelan, D. et al. Epidemiologic transition of lung cancer mortality in Italy by sex, province of residence and birth cohort (1920–1929 to 1960–1969). Int. J. Cancer. 153(10), 1746–1757. https://doi.org/10.1002/ijc.34657 (2023).
doi: 10.1002/ijc.34657
pubmed: 37486208
Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF (publ.). Leitlinienprogramm Onkologie: Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms (Langversion 1.0). AWMF-Registernummer: 020/007OL. http://leitlinienprogramm-onkologie.de/Lungenkarzinom.98.0.html . Accessed 27 June 2022 (2018).
Vinod, S. K. & Hau, E. Radiotherapy treatment for lung cancer: Current status and future directions. Respirology 25(Suppl 2), 61–71. https://doi.org/10.1111/resp.13870 (2020).
doi: 10.1111/resp.13870
pubmed: 32516852
Palma, D. et al. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: A population-based time-trend analysis. J. Clin. Oncol. 28(35), 5153–5159. https://doi.org/10.1200/JCO.2010.30.0731 (2010).
doi: 10.1200/JCO.2010.30.0731
pubmed: 21041709
Kraywinkel, K. et al. Nationwide statements from regional data: Methods of the Center for Cancer Registry Data. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 57(1), 13–21. https://doi.org/10.1007/s00103-013-1878-z (2014).
doi: 10.1007/s00103-013-1878-z
pubmed: 24357167
Krebs - Version Epi2020_1. (n.d.). Krebsdaten.de. https://www.krebsdaten.de/Krebs/DE/Content/Scientific_Use_File/Versionen/epi2020_1/epi2020_1_node.html . Accessed 1 June 2022.
Hundsdörfer, G. Epidemiological cancer registries in Germany: History from a legal point of view: Historie im Wandel rechtlicher Vorgaben. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 57(1), 7–12. https://doi.org/10.1007/s00103-013-1874-3 (2014).
doi: 10.1007/s00103-013-1874-3
pubmed: 24357166
Zentrum für Krebsregisterdaten (ZfKD) im Robert Koch-Institut. Datensatz des ZfKD auf Basis der epidemiologischen Landeskrebsregisterdaten, verfügbare Diagnosejahre bis 2018. Version: Epi2020_1. https://doi.org/10.18444/5.03.01.0005.0016.0001 (2021).
Rossi, S. et al. The EUROCARE-5 study on cancer survival in Europe 1999–2007: Database, quality checks and statistical analysis methods. Eur. J. Cancer 51(15), 2104–2119. https://doi.org/10.1016/j.ejca.2015.08.001 (2015).
doi: 10.1016/j.ejca.2015.08.001
pubmed: 26421815
World Health Organization (WHO). International classification of diseases for oncology ICD-O (3rd edn.) (World Health Organization, 2014).
Lim, W., Ridge, C. A., Nicholson, A. G. & Mirsadraee, S. The 8th lung cancer TNM classification and clinical staging system: Review of the changes and clinical implications. Quant. Imaging Med. Surg. 8(7), 709–718. https://doi.org/10.21037/qims.2018.08.02 (2018).
doi: 10.21037/qims.2018.08.02
pubmed: 30211037
pmcid: 6127520
Mirsadraee, S. et al. The 7th lung cancer TNM classification and staging system: Review of the changes and implications. World J. Radiol. 4(4), 128–134. https://doi.org/10.4329/wjr.v4.i4.128 (2012).
doi: 10.4329/wjr.v4.i4.128
pubmed: 22590666
pmcid: 3351680
R version 2023.06.1, R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/ (2023).
Krebs-Informationen zum Datensatz. (n.d.). Krebsdaten.de. https://www.krebsdaten.de/Krebs/DE/Content/Scientific_Use_File/Info_datensatz/info_datensatz_node.html . Accessed 2 June 2022.
Mattar, E. H. Integrated PET/CT in imaging of non-small cell lung cancer. J. Egypt. Natl. Cancer Inst. 19(4), 263–274 (2007).
Ko, E. C., Raben, D. & Formenti, S. C. The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer. Clin. Cancer Res. 24(23), 5792–5806. https://doi.org/10.1158/1078-0432.CCR-17-3620 (2018).
doi: 10.1158/1078-0432.CCR-17-3620
pubmed: 29945993
Slotman, B. J. et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: Short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. J. Clin. Oncol. 27(1), 78–84. https://doi.org/10.1200/JCO.2008.17.0746 (2009).
doi: 10.1200/JCO.2008.17.0746
pubmed: 19047288
Hiddemann, W., Bartram, C. R. (publ.). Die Onkologie: Teil 1: Epidemiologie—Pathogenese-Grundprinzipien der Therapie; Teil 2: Solide Tumoren-Lymphome-Leukämien (2. Aufl.). https://doi.org/10.1007/978-3-540-79725-8 (Springer, 2009).
Mons, U., Pust, S., Pötschke-Langer, M., Krebsforschungszentrum, D. & (publ.).,. Frauen und Rauchen in Deutschland (Deutsches Krebsforschungszentrum, 2008).
Herold, G. Innere Medizin 2021 (de Gruyter, 2021).
doi: 10.1515/9783110738896
Heilert, D., & Kaul, A. Smoking behaviour in Germany: Evidence from the SOEP, SOEPpapers on Multidisciplinary Panel Data Research, No. 920, Deutsches Institut für Wirtschaftsforschung (DIW), Berlin (2017).
Howlader, N. et al. The effect of advances in lung-cancer treatment on population mortality. N. Engl. J. Med. 383(7), 640–649. https://doi.org/10.1056/NEJMoa1916623 (2020).
doi: 10.1056/NEJMoa1916623
pubmed: 32786189
pmcid: 8577315
Rittberg, R. et al. Real-world outcomes of stage IV NSCLC with PD-L1 ≥ 50% treated with first-line pembrolizumab: Uptake of second-line systemic therapy. Curr. Oncol. 30(6), 5299–5308. https://doi.org/10.3390/curroncol30060402 (2023).
doi: 10.3390/curroncol30060402
pubmed: 37366885
pmcid: 10297524
Bedir, A. et al. Socioeconomic disparities in head and neck cancer survival in Germany: A causal mediation analysis using population-based cancer registry data. J. Cancer Res. Clin. Oncol. 147(5), 1325–1334. https://doi.org/10.1007/s00432-021-03537-2 (2021).
doi: 10.1007/s00432-021-03537-2
pubmed: 33569714
pmcid: 8021523
Bedir, A., Abera, S. F., Vordermark, D. & Medenwald, D. Socioeconomic disparities in endometrial cancer survival in Germany: A survival analysis using population-based cancer registry data. J. Cancer Res. Clin. Oncol. https://doi.org/10.1007/s00432-021-03908-9 (2022).
doi: 10.1007/s00432-021-03908-9
pubmed: 35064816
pmcid: 9015991
Efremov, L., Abera, S. F., Bedir, A., Vordermark, D. & Medenwald, D. Patterns of glioblastoma treatment and survival over a 16-years period: Pooled data from the German Cancer Registries. J. Cancer Res. Clin. Oncol. 147(11), 3381–3390. https://doi.org/10.1007/s00432-021-03596-5 (2021).
doi: 10.1007/s00432-021-03596-5
pubmed: 33743072
pmcid: 8484256
Roshkovan, L. et al. Alveolar adenoma of the lung: multidisciplinary case discussion and review of the literature. J. Thorac. Dis. 12(11), 6847–6853. https://doi.org/10.21037/jtd-20-1831 (2020).
doi: 10.21037/jtd-20-1831
pubmed: 33282386
pmcid: 7711389